Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions

Future Oncology · Published 2026-05-27 · DOI 10.1080/14796694.2026.2673807

Free full text

Authors (5)

Luisa Nader, Paula Hoffmeister-Wittmann, Georg Martin Haag, Rene Jackstadt, Bruno Christian Köhler

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Nader, L., Hoffmeister-Wittmann, P., Haag, G., et al. (2026). Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions. Future Oncology. https://doi.org/10.1080/14796694.2026.2673807

Related articles

• Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · Future Oncology · 2026 · Same journal
• Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · Future Oncology · 2026 · Same journal
• Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · Future Oncology · 2026 · Same journal
• Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · Future Oncology · 2026 · Same journal
• Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · Future Oncology · 2026 · Same journal
• IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · Future Oncology · 2026 · Same journal
• Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · Future Oncology · 2026 · Same journal
• A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer · Future Oncology · 2026 · Same journal
• Treatment outcomes with palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer who also have cardiovascular diseases: a plain language summary · Future Oncology · 2026 · Same journal
• A Naples prognostic score-based nomogram enhances perioperative risk stratification for resected pancreatic cancer · Future Oncology · 2026 · Same journal